Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:ADMANYSE:AMAMNASDAQ:EXAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.25+4.9%$0.27$0.20▼$1.48$67.38M2.241.71 million shs808,155 shsADMAADMA Biologics$20.40-2.0%$20.99$10.21▼$25.67$4.87B0.473.67 million shs2.80 million shsAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/AEXAIExscientia$4.84$4.97$3.80▼$6.49$632.93M0.83663,980 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%-14.38%-12.81%-46.95%-76.01%ADMAADMA Biologics0.00%+0.97%+5.69%+11.46%+95.77%AMAMAmbrx Biopharma0.00%0.00%0.00%0.00%0.00%EXAIExscientia0.00%0.00%0.00%0.00%-3.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics3.0061 of 5 stars4.25.00.00.01.60.80.0ADMAADMA Biologics2.375 of 5 stars2.61.00.00.02.82.51.9AMAMAmbrx BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AEXAIExscientia0.2172 of 5 stars1.00.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.43Hold$1.52497.30% UpsideADMAADMA Biologics 3.25Buy$24.2518.87% UpsideAMAMAmbrx Biopharma 0.00N/AN/AN/AEXAIExscientia 2.00Hold$5.003.31% UpsideCurrent Analyst Ratings BreakdownLatest ADAP, EXAI, AMAM, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/26/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.753/21/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.503/21/2025ADAPAdaptimmune TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.40(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$179.64M0.38N/AN/A$0.17 per share1.50ADMAADMA Biologics$459.38M10.60$0.07 per share311.70$0.60 per share34.00AMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18EXAIExscientia$25.60M24.72N/AN/A$2.54 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%8/11/2025 (Estimated)ADMAADMA Biologics-$28.24M$0.8572.8629.57N/A17.80%53.20%26.07%8/6/2025 (Estimated)AMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/AEXAIExscientia-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/ALatest ADAP, EXAI, AMAM, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million3/24/2025Q4 2024ADAPAdaptimmune Therapeutics-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AEXAIExscientiaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics0.623.853.82ADMAADMA Biologics0.487.093.26AMAMAmbrx BiopharmaN/A13.2813.28EXAIExscientia0.064.544.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%ADMAADMA Biologics75.68%AMAMAmbrx Biopharma77.28%EXAIExscientia41.58%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%ADMAADMA Biologics3.50%AMAMAmbrx Biopharma0.64%EXAIExscientia16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million224.05 millionOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableEXAIExscientia280130.77 million109.32 millionOptionableADAP, EXAI, AMAM, and ADMA HeadlinesRecent News About These CompaniesExscientia claims world first as AI-created drug enters clinicMarch 7, 2025 | pharmaphorum.comRecursion, Exscientia, and AI drug discovery’s moment of truthDecember 26, 2024 | pharmaphorum.comTrans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia CombineNovember 21, 2024 | genengnews.comExscientia and Recursion Merge to Revolutionize Drug DiscoveryNovember 21, 2024 | markets.businessinsider.comRecursion, Exscientia officially combine to advance drug discoveryNovember 21, 2024 | markets.businessinsider.comRecursion: No News Isn't Good News When It Comes To Vanilla PipelineNovember 20, 2024 | seekingalpha.comBarclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)November 15, 2024 | markets.businessinsider.comRecursion and Exscientia Merger Approved by ShareholdersNovember 14, 2024 | markets.businessinsider.comRecursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13, 2024 | finanznachrichten.deRecursion, Exscientia shareholders approve proposed combinationNovember 13, 2024 | markets.businessinsider.comAnother big AI deal as Sanofi taps Exscientia for 15 new drugsNovember 6, 2024 | pharmaphorum.comExscientia Plc Enhances Board Collaboration with RecursionNovember 6, 2024 | markets.businessinsider.comVet tranquillizer increases overdose deaths in Yukon, health minister saysOctober 12, 2024 | msn.comBoeing Sacks 17,000 Workers Amid Strike and Safety ConcernsOctober 12, 2024 | nz.finance.yahoo.comRecursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug DiscoveryOctober 12, 2024 | msn.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAIOctober 11, 2024 | accesswire.comCapricor reports positive long-term data for DMD drug deramiocelOctober 11, 2024 | msn.comExscientia Set for Strategic Acquisition by RecursionOctober 11, 2024 | finance.yahoo.comRecursion, Exscientia seek support for merger ahead of special meetingOctober 10, 2024 | seekingalpha.comExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024October 9, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAP, EXAI, AMAM, and ADMA Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.25 +0.01 (+4.91%) Closing price 04:00 PM EasternExtended Trading$0.26 +0.00 (+0.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.ADMA Biologics NASDAQ:ADMA$20.40 -0.41 (-1.97%) Closing price 04:00 PM EasternExtended Trading$20.22 -0.18 (-0.88%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Ambrx Biopharma NYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Exscientia NASDAQ:EXAIExscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
